Clinical Relevance of Hepatic and Renal P‐gp/ <scp>BCRP</scp> Inhibition of Drugs: An International Transporter Consortium Perspective-Reference-Cited by-同舟云学术

Clinical Relevance of Hepatic and Renal P‐gp/ BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Published:2022-06-22 Issue:3 Volume:112 Page:573-592
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Taskar Kunal S.¹^ORCID,Yang Xinning²^ORCID,Neuhoff Sibylle³^ORCID,Patel Mitesh⁴,Yoshida Kenta⁵^ORCID,Paine Mary F.⁶^ORCID,Brouwer Kim L.R.⁷^ORCID,Chu Xiaoyan⁸^ORCID,Sugiyama Yuichi⁹^ORCID,Cook Jack¹⁰^ORCID,Polli Joseph W.¹¹,Hanna Imad¹²,Lai Yurong¹³^ORCID,Zamek‐Gliszczynski Maciej¹⁴,

Affiliation:

1. Drug Metabolism and Pharmacokinetics IVIVT, GlaxoSmithKline Stevenage UK

2. Office of Clinical Pharmacology Center of Drug Evaluation and Research, US Food and Drug Administration Silver Spring Maryland USA

3. Certara UK Ltd. Simcyp Division Sheffield UK

4. Novartis Institutes for BioMedical Research Cambridge Massachusetts USA

5. Clinical Pharmacology, Genentech Early Research and Development South San Francisco California USA

6. Department of Pharmaceutical Sciences College of Pharmacy and Pharmaceutical Sciences Washington State University Spokane Washington USA

7. Division of Pharmacotherapy and Experimental Therapeutics UNC Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

8. Department of ADME and Discovery Toxicology Merck & Co., Inc. Kenilworth New Jersey USA

9. Laboratory of Quantitative System PK/Pharmacodynamics School of Pharmacy Josai International University Tokyo Japan

10. Clinical Pharmacology, Global Product Development Pfizer Inc. Groton Connecticut USA

11. Global Medical Sciences ViiV Healthcare Research Triangle Park North Carolina USA

12. Pharmacokinetic Sciences‐Oncology Novartis Institute for Biomedical Research East Hanover New Jersey USA

13. Drug Metabolism, Gilead Sciences Inc. Foster City California USA

14. Drug Metabolism and Pharmacokinetics IVIVT, GlaxoSmithKline Upper Providence Pennsylvania USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2670

Reference100 articles.

1. Progress in the study of D-α-tocopherol polyethylene glycol 1000 succinate (TPGS) reversing multidrug resistance

2. Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor

3. Why Clinical Modulation of Efflux Transport at the Human Blood–Brain Barrier Is Unlikely: The ITC Evidence-Based Position

4. DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

5. Abundance of Drug Transporters in the Human Kidney Cortex as Quantified by Quantitative Targeted Proteomics

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Membrane transporters in drug development and as determinants of precision medicine;Nature Reviews Drug Discovery;2024-01-24

2. Performance and Sensitivity of [^99mTc]Tc-sestamibi Compared with Positron Emission Tomography Radiotracers to Measure P-glycoprotein Function in the Kidneys and Liver;Molecular Pharmaceutics;2024-01-15

3. Regulatory Considerations in Metabolism‐ and Transport‐Based Drug Interactions;Oral Bioavailability and Drug Delivery;2023-10-10

4. Enhanced Cellular Uptake and Transport of Bovine Lactoferrin Using Pectin- and Chitosan-Modified Solid Lipid Nanoparticles;Pharmaceutics;2023-08-21

5. Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance;Pharmacology & Therapeutics;2023-08